Health care costs and treatment patterns among metastatic pancreatic cancer (MPC) patients (pts) initiating first-line (1L) on nab-paclitaxel/gemcitabine (nab-P+G) or FOLFIRINOX (FFX).

Abstract

415 Background: The economic burden of MPC is substantial while treatment options are limited. This study aimed to compare healthcare costs and treatment patterns in MPC patients who initiated nab-P+G or FFX in a large insured US population. Methods: A retrospective study was conducted using the Truven Health MarketScan administrative claims databases. Adults who had ≥2 claims for pancreatic cancer, ≥1 claim with a secondary malignancy, completed ≥ 1 cycle of nab-P+G or FFX as 1L during 1/1/2013 and 3/31/2015, and had continuous enrollment in health plans for ≥6 months prior to and 3 months following the start of 1L were selected. Total healthcare costs and MPC-related treatment costs were measured per patient per month (PPPM) during 1L. Kaplan-Meier curve was used to describe time to treatment discontinuation (TTD) between groups. Results: 550 MPC patients met selection criteria ( nab-P+G, n=294; FFX, n=256). Patients on nab-P+G were significantly older (mean age: 63.6 vs 58.8 years; p<0.001) and had higher counts of unique diagnostic categories (21.2 vs 19.0, p<0.001) vs FFX. There was no significant difference in median TTD of 1L (3.8 vs 4 months; log-rank test p=0.602) between nab-P+G and FFX. Compared with FFX, nab-P+G pts had higher chemotherapy drug costs but incurred lower total healthcare, supportive care, and treatment administration costs (Table). Conclusions: This claims analysis suggests patients treated with FFX had similar treatment duration and higher total healthcare costs driven by treatment administration and supportive care. Table: Mean Healthcare and Select MPC-related Treatment Costs During 1L (PPPM) [Table: see text]